Table of Contents:

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Drug Class

  2.3.2 Market Size by Route of Administration

  2.3.3 Market Size by End User

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 API & Raw Material Suppliers

  3.4.2 Osteoarthritis Drug Manufacturers & Biopharmaceutical Companies

  3.4.3 Distributors, Wholesalers & Pharmacy Networks

  3.4.4 End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Disease Prevalence & Patient Population Metrics

4.1.1 Share (%) of osteoarthritis patients by knee, hip, hand, spine, and other affected joints globally.

4.1.2 Growth (%) in diagnosed osteoarthritis cases during 2025 and 2026.

4.1.3 Increase (%) in the aging population contributing to osteoarthritis incidence worldwide.

4.2 Therapeutics & Drug Utilization Metrics

4.2.1 Share (%) of osteoarthritis treatment demand by NSAIDs, corticosteroids, visco supplements, analgesics, biologics, and other drug classes globally.

4.2.2 Growth (%) in prescription volumes for osteoarthritis therapeutics across major healthcare markets.

4.2.3 Increase (%) in adoption of non-opioid pain management therapies globally.

4.3 Healthcare Spending & Treatment Access Metrics

4.3.1 Share (%) of osteoarthritis-related healthcare expenditure across pharmaceuticals, surgery, rehabilitation, and supportive care globally.

4.3.2 Growth (%) in healthcare spending directed toward musculoskeletal disease management worldwide.

4.3.3 Increase (%) in patient access to advanced osteoarthritis therapies and specialty treatments globally.

4.4 Clinical Research & Innovation Metrics

4.4.1 Share (%) of osteoarthritis clinical trials focused on disease-modifying therapies, regenerative medicine, biologics, and novel pain management approaches globally.

4.4.2 Growth (%) in R&D investments targeting osteoarthritis treatment development worldwide.

4.4.3 Increase (%) in regulatory approvals and pipeline advancements for osteoarthritis therapeutics globally.

4.5 Regional Healthcare & Market Metrics

4.5.1 Share (%) of global osteoarthritis therapeutics demand across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

4.5.2 Growth (%) in musculoskeletal disease treatment adoption across major economies.

4.5.3 Increase (%) in orthopedic care infrastructure and arthritis management programs globally.

5. Osteoarthritis Therapeutics Market Segmental Analysis & Forecast, By Drug Class, 2022–2035, Value (USD Billion)

5.1 Introduction

5.2 NSAIDs

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022 – 2035

5.3 Corticosteroids

5.4 Hyaluronic Acid

5.5 Disease-Modifying Osteoarthritis Drugs (DMOADs)

5.6 Opioids

5.7 Others

6. Osteoarthritis Therapeutics Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 Oral

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022 – 2035

   6.3 Topical

   6.4 Intra-Articular Injections

   6.5 Others

7. Osteoarthritis Therapeutics Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)

7.1 Introduction

7.2 Hospitals

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022 – 2035

7.3 Orthopaedic Clinics

7.4 Rehabilitation Centres

7.5 Retail Pharmacies

8. Osteoarthritis Therapeutics Market Segmental Analysis & Forecast, By Region, 2022 – 2035, Value (USD Billion)

8.1 Introduction

8.2 North America

 8.2.1 Key Trends

 8.2.2 Osteoarthritis Therapeutics Market Size & Forecast, By Drug Class, 2022–2035

 8.2.3 Osteoarthritis Therapeutics Market Size & Forecast, By Route of Administration, 2022–2035

 8.2.4 Osteoarthritis Therapeutics Market Size & Forecast, By End User, 2022–2035

 8.2.5 Osteoarthritis Therapeutics Market Size & Forecast, By Country, 2022–2035

  8.2.5.1 USA

  8.2.5.2 Canada

8.3 Europe

 8.3.1 Key Trends

 8.3.2 Osteoarthritis Therapeutics Market Size & Forecast, By Drug Class, 2022–2035

 8.3.3 Osteoarthritis Therapeutics Market Size & Forecast, By Route of Administration, 2022–2035

 8.3.4 Osteoarthritis Therapeutics Market Size & Forecast, By End User, 2022–2035

 8.3.5 Osteoarthritis Therapeutics Market Size & Forecast, By Country, 2022–2035

  8.3.5.1 Germany

  8.3.5.2 UK

  8.3.5.3 France

  8.3.5.4 Italy

  8.3.5.5 Spain

  8.3.5.6 Russia

  8.3.5.7 Poland

  8.3.5.8 Rest of Europe

8.4 Asia-Pacific

 8.4.1 Key Trends

 8.4.2 Osteoarthritis Therapeutics Market Size & Forecast, By Drug Class, 2022–2035

 8.4.3 Osteoarthritis Therapeutics Market Size & Forecast, By Route of Administration, 2022–2035

 8.4.4 Osteoarthritis Therapeutics Market Size & Forecast, By End User, 2022–2035

 8.4.5 Osteoarthritis Therapeutics Market Size & Forecast, By Country, 2022–2035

  8.4.5.1 China

  8.4.5.2 India

  8.4.5.3 Japan

  8.4.5.4 South Korea

  8.4.5.5 Australia

  8.4.5.6 ASEAN Countries

  8.4.5.7 Rest of Asia-Pacific

8.5 Latin America

 8.5.1 Key Trends

 8.5.2 Osteoarthritis Therapeutics Market Size & Forecast, By Drug Class, 2022–2035

 8.5.3 Osteoarthritis Therapeutics Market Size & Forecast, By Route of Administration, 2022–2035

 8.5.4 Osteoarthritis Therapeutics Market Size & Forecast, By End User, 2022–2035

 8.5.5 Osteoarthritis Therapeutics Market Size & Forecast, By Country, 2022–2035

  8.5.5.1 Brazil

  8.5.5.2 Argentina

  8.5.5.3 Mexico

  8.5.5.4 Colombia

  8.5.5.5 Rest of Latin America

8.6 Middle East & Africa

 8.6.1 Key Trends

 8.6.2 Osteoarthritis Therapeutics Market Size & Forecast, By Drug Class 2022–2035

 8.6.3 Osteoarthritis Therapeutics Market Size & Forecast, By Route of Administration, 2022–2035

 8.6.4 Osteoarthritis Therapeutics Market Size & Forecast, By End User, 2022–2035

 8.6.5 Osteoarthritis Therapeutics Market Size & Forecast, By Country, 2022–2035

  8.6.5.1 UAE

  8.6.5.2 Saudi Arabia

  8.6.5.3 Qatar

  8.6.5.4 South Africa

  8.6.5.5 Rest of Middle East & Africa

9. Competitive Landscape

 9.1 Key Players' Positioning

 9.2 Competitive Developments

  9.2.1 Key Strategies Adopted (%), By Key Players, 2025

  9.2.2 Year-Wise Strategies & Development, 2022 – 2035

  9.2.3 Number of Strategies Adopted by Key Players, 2025

 9.3 Market Share Analysis, 2025

 9.4 Product/Service & Application Benchmarking

  9.4.1 Product/Service Specifications & Features by Key Players

  9.4.2 Product/Service Heatmap by Key Players

  9.4.3 Application Heatmap by Key Players

 9.5 Industry Start-Up & Innovation Landscape

9.6 Key Company Profiles

9.6.1 Pfizer Inc.

  9.6.1.1 Company Overview & Snapshot

  9.6.1.2 Product/Service Portfolio

  9.6.1.3 Key Company Financials

  9.6.1.4 SWOT Analysis

9.6.2 Johnson & Johnson (Janssen Pharmaceuticals)

9.6.3 Sanofi S.A.

9.6.4 Eli Lilly and Company

9.6.5 AbbVie Inc.

9.6.6 Novartis AG

9.6.7 GlaxoSmithKline PLC

9.6.8 Anika Therapeutics Inc.

9.6.9 Bioventus LLC

9.6.10 Eupraxia Pharmaceuticals Inc.

9.6.11 Sun Pharmaceutical Industries Ltd.

9.6.12 Boehringer Ingelheim GmbH

9.6.13 Dr. Reddy’s Laboratories Ltd.

9.6.14 Assertio Holdings Inc.

9.6.15 Horizon Therapeutics PLC (Amgen)

9.6.16 Galapagos NV

9.6.17 Merck KGaA (Sprifermin)

9.6.18 Pacira BioSciences Inc.

9.6.19 Teva Pharmaceutical Industries Ltd.

9.6.20 Collegium Pharmaceutical Inc.

10. Analyst Recommendations

 10.1 SNS Insider Opportunity Map

 10.2 Industry Low-Hanging Fruit Assessment

 10.3 Market Entry & Growth Strategy

 10.4 Analyst Viewpoint & Suggestions on Market Growth

11. Assumptions

12. Disclaimer

13. Appendix

 13.1 List of Tables

 13.2 List of Figures